Judges side with FDA in rejecting stem cell device

(AP)—A federal appeals court is siding with the Food and Drug Administration in a case brought by medical device maker Cytori, ruling that the agency was correct to reject fast-track approval for two company devices used to process adult stem cells.

Cytori makes the Celution and StemSource devices which separate from fat tissue using a combination of spinning motions and . The company asked the FDA to approve the devices using a fast-track pathway reserved for devices that are similar to products already on the market. Cytori argued that its devices are similar to devices used to process blood and bone marrow.

A three-judge panel said the FDA was right to reject that argument and to require the company to apply through a more rigorous process.

3.7 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

FDA aims to accelerate medical device reviews

Feb 08, 2011

(AP) -- Federal health officials have proposed a plan that would speed up the approval of innovative medical devices that hold the potential to dramatically improve patients' lives.

FDA plans modest changes to medical device system

Jan 19, 2011

(AP) -- The Food and Drug Administration is laying out plans to update the 35-year-old system used to approve most medical devices, which has been subject to increasing criticism by public safety advocates.

FDA medical device approvals get external review

Sep 23, 2009

(AP) -- The Food and Drug Administration is asking the government's top medical advisers to review its system for approving certain types of medical devices, which has been criticized by safety advocates and government watchdogs.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

16 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

nanotech_republika_pl
not rated yet Mar 23, 2013
They will move to Mexico.